Lakewood-Amedex Biotherapeutics, Inc. (LABT)
| Market Cap | 1.85M |
| Revenue (ttm) | n/a |
| Net Income | -8.97M |
| EPS | -10.20 |
| Shares Out | 2.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,052 |
| Open | 0.7931 |
| Previous Close | 0.7920 |
| Day's Range | 0.7800 - 0.8211 |
| 52-Week Range | 0.7610 - 98.2000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 18, 2026 |
About LABT
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biother... [Read more]
Financial Performance
Financial StatementsNews
Lakewood-Amedex announces preclinical data from Bisphosphocin studies
Lakewood-Amedex Biotherapeutics (LABT) announced positive preclinical data in urinary tract infection, or UTI, and pulmonary infection indications in animal models treated with Bisphosphocin compounds...
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Intravesical administration of the Bisphosphocin ® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E.
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting,...
Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?
Lakewood-Amedex Biotherapeutics stock rallied on Monday after it announced new data for its lead candidate.
Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study
Lakewood-Amedex Biotherapeutics (LABT) announced positive Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being investigate...
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
Lead candidate Nu-3 is a topically formulated Bisphosphocin ® , designed to rapidly kill microbes while reducing the risk of antimicrobial resistance SARASOTA, Fla., Sept. 28, 2026 /PRNewswire/ -- Lak...
Lakewood-Amedex Biotherapeutics: First patient dosed in Phase2a trial of Nu-3
Lakewood-Amedex Biotherapeutics (LABT) announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic foot u...
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin ® antimicrobial platform Topline data expected in ...
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Clinical and Corporate Highlights Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolution Strengthened balance sheet t...
Lakewood-Amedex Biotherapeutics files to sell 4.51M shares of common for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 4.51M shares of common stock. The company is not selling any…
Lakewood-Amedex Biotherapeutics cleared for Phase 2a trial of Nu-3
Lakewood-Amedex Biotherapeutics (LABT) announced that it has obtained central and all site Institutional Review Board approvals and confirmed clinical trial site readiness to commence its Phase 2a cli...
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
SARASOTA, Fla., Sept. 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-actin...
Lakewood-Amedex Biotherapeutics Registration statement: Registration filing
Lakewood-Amedex Biotherapeutics filed a registration statement on September 18, 2026, providing details about a securities offering with the SEC.
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting...
Lakewood-Amedex Biotherapeutics Quarterly report: Q2 2026
Lakewood-Amedex Biotherapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Lakewood-Amedex Biotherapeutics Proxy statement: Proxy filing
Lakewood-Amedex Biotherapeutics filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
Lakewood-Amedex Biotherapeutics Proxy statement: Proxy filing
Lakewood-Amedex Biotherapeutics filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
Lakewood-Amedex Biotherapeutics Proxy statement: Proxy filing
Lakewood-Amedex Biotherapeutics filed a proxy statement on July 30, 2026, providing details for shareholder voting and corporate governance matters.
Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up Today?
Lakewood-Amedex Biotherapeutics stock soared after the company reported that Nu-3 showed a high barrier to resistance in lab tests.
Lakewood-Amedex announces resistance data for Nu-3
Lakewood-Amedex Biotherapeutics (LABT) announced resistance data for Nu-3 in alignment with the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria, or PACCARB. The 27th Public Me...
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demons...
Lakewood-Amedex announces preclinical data from Phase 2a clinical trial
Lakewood-Amedex Biotherapeutics (LABT) announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in its upcoming Phase 2a clinical trial. “These preclin...
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects. SARASOTA, Fla.
Lakewood-Amedex supports reintroduction of PASTEUR act
Lakewood-Amedex Biotherapeutics (LABT) announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, PASTEUR, Act, legislation desi...
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Company highlights its differentiated Bisphosphocin ® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development SARAS...